학술논문
SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Document Type
Article
Author
Source
Retina; June 2022, Vol. 42 Issue: 6 p1038-1046, 9p
Subject
Language
ISSN
0275004X; 15392864
Abstract
Supplemental Digital Content is Available in the Text.In patients with treatment-naive neovascular age-related macular degeneration, 6 weeks of orally administered AKST4290 was well-tolerated and associated with improved best-corrected visual acuity scores. AKST4290 is being developed as a potential oral alternative for the treatment of neovascular age-related macular degeneration, and further studies are warranted.